MYC and head and neck cancer: Anso and colleagues (30) identified the capacity of c-MYC to attenuate both baseline OCR and spare respiratory capacity in osteogenic sarcoma models and Sandulache and colleagues (31) identified a diminished spare respiratory capacityinp53 mutated head and neck cancer models.